全球智库信息集成服务系统(G2TT): A molecular monopoly? HPV testing, the Pap smear and the molecularisation of cervical cancer in the USA.

G2TT

来源类型	Article
规范类型	其他
DOI	10.1111/j.1467-9566.2011.01411.x
ISBN	0141-9889
	A molecular monopoly? HPV testing, the Pap smear and the molecularisation of cervical cancer in the USA.
	Hogarth, Stuart; Hopkins, Michael M; Rodriguez, Victor
发表日期	2012
出处	Sociology of Health and Illness
出版者	Wiley-Blackwell
出版年	2012
页码	234-250
语种	英语
摘要	DNA-based molecular testing for Human Papillomavirus (HPV) has emerged as a novel approach to cervical cancer screening in the context of well entrenched prior technology, the Pap smear. This paper seeks to elucidate the process of molecularisation (Clarke et al. 2003) in the context of screening programmes. We illustrate how, although Pap has long been problematised and could be seen as a competing technological option, the existing networks, and regime for Pap were important in supporting the entrenchment process for the artefacts, techniques, and new diagnostics industry entrant Digene, associated with the new test. The paper provides insights into how molecularisation of screening unfolds in a mainstream market. We reveal an incremental, accretive, rather than revolutionary process led by new commercial interests in an era when diagnostic innovation is increasingly privatised. We show Digene's reliance on patents, an international scientific network, and their position as an obligatory passage point in the clinical research field with regard to the new technology's role, as well as controversial new marketing practices. The paper is based on a mixed method approach, drawing on a wide range of contemporary sources (including patents, statutory filings by companies, scientific literature, and news sources) as well as interviews.
URL	http://sro.sussex.ac.uk/id/eprint/16738/
来源智库	Science Policy Research Unit (United Kingdom)
引用统计
资源类型	智库出版物
条目标识符	http://119.78.100.153/handle/2XGU8XDN/467951
推荐引用方式 GB/T 7714	Hogarth, Stuart,Hopkins, Michael M,Rodriguez, Victor. A molecular monopoly? HPV testing, the Pap smear and the molecularisation of cervical cancer in the USA.. 2012.